Neurology 2002;59:1412-1420
© 2002 American Academy of Neurology
Eight-year follow-up study of brain atrophy in patients with MS
E. Fisher, PhD,
R. A. Rudick, MD,
J. H. Simon, MD PhD,
G. Cutter, PhD,
M. Baier, MS,
J. -C. Lee, MS,
D. Miller, PhD,
B. Weinstock-Guttman, MD,
M. K. Mass, MD,
D. S. Dougherty, MD and
N. A. Simonian, MD
From the Whitaker Biomedical Imaging Laboratory (Dr. Fisher), Department of Biomedical Engineering, Mellen Center for Multiple Sclerosis Treatment and Research (Drs. Rudick and Miller), and Department of Biostatistics and Epidemiology (Dr. Lee), The Cleveland Clinic Foundation, OH; Department of Radiology (Dr. Simon), University of Colorado Health Sciences Center, Denver; University of Nevada (Dr. Cutter), Reno; Center for Research Methodology and Biometrics (Dr. Baier), AMC Cancer Research Center, Denver, CO; Department of Neurology (Dr. Weinstock-Guttman), Buffalo General Hospital, NY; Department of Neurology (Dr. Mass), Oregon Health Sciences University, Portland; Department of Neurology (Dougherty), Thomas Jefferson University, Philadelphia, PA; and Millennium Pharmaceuticals, Inc. (Dr. Simonian), Cambridge, MA.
Address correspondence and reprint requests to Dr. Elizabeth Fisher, Department of Biomedical Engineering, ND20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: fisher{at}bme.ri.ccf.org
Objective: To characterize whole-brain atrophy in relapsing-remitting MS (RRMS) patients over an 8-year period. The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correlates of atrophy progression.
Methods: A follow-up study was conducted to reassess patients from a phase III trial of interferon ß-1a (IFNß-1a) 8 years after randomization. Clinical and MRI data from 172 patients followed over 2 years in the original trial were used as baseline data. Follow-up data were obtained on 160 patients, including 134 patients with follow-up MRI examinations. Brain atrophy was estimated by automated calculation of brain parenchymal fraction. The relation between atrophy during the original trial and disability status at follow-up was determined. Correlations were also determined between lesion measurements from the original trial and the brain parenchymal fraction at follow-up.
Results: Brain atrophy was correlated with subsequent disability status. Atrophy rate during the original trial was the most significant MRI predictor of disability status at follow-up. Brain atrophy at follow-up was related to lesion volumes measured during the original trial.
Conclusions: The relation between atrophy progression and subsequent neurologic disability status suggests that atrophy progression during RRMS is clinically relevant. Therefore, atrophy progression may be a useful marker for disease progression in clinical trials. The relation between lesions and subsequent atrophy indicates that brain atrophy may be related to focal tissue damage at earlier points in time, but important predisposing or other factors contributing to atrophy remain undefined.
This article has been cited by other articles:
|
|
|
|
 
M Di Filippo, V M Anderson, D R Altmann, J K Swanton, G T Plant, A J Thompson, and D H Miller
Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes
J. Neurol. Neurosurg. Psychiatry,
February 1, 2010;
81(2):
204 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Leist and S. Marks
Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics
Neurology,
January 5, 2010;
74(1_Supplement_1):
S54 - S61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Goodin and D. Bates
Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode
Multiple Sclerosis,
October 1, 2009;
15(10):
1175 - 1182.
[Abstract]
[PDF]
|
|
|
|
|
|
|
U. Walter, S. Wagner, S. Horowski, R. Benecke, and U. K. Zettl
Transcranial brain sonography findings predict disease progression in multiple sclerosis
Neurology,
September 29, 2009;
73(13):
1010 - 1017.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Carroll
Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit
Multiple Sclerosis,
August 1, 2009;
15(8):
951 - 958.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Minneboo, B. Uitdehaag, P Jongen, H Vrenken, D. Knol, M. van Walderveen, C. Polman, J. Castelijns, and F Barkhof
Association between MRI parameters and the MS severity scale: a 12 year follow-up study
Multiple Sclerosis,
May 1, 2009;
15(5):
632 - 637.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T Korteweg, M Rovaris, V Neacsu, M Filippi, G Comi, B. Uitdehaag, D. Knol, C. Polman, F Barkhof, H Vrenken, et al.
Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
Multiple Sclerosis,
April 1, 2009;
15(4):
465 - 471.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Gauthier, A. M. Berger, Z. Liptak, Y. Duan, S. Egorova, G. J. Buckle, B. I. Glanz, S. J. Khoury, R. Bakshi, H. L. Weiner, et al.
Rate of Brain Atrophy in Benign vs Early Multiple Sclerosis
Arch Neurol,
February 1, 2009;
66(2):
234 - 237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Tedeschi, D Dinacci, M Comerci, L Lavorgna, G Savettieri, A Quattrone, P Livrea, F Patti, V Brescia Morra, G Servillo, et al.
Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study
Multiple Sclerosis,
February 1, 2009;
15(2):
204 - 211.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Furby, T Hayton, V Anderson, D Altmann, R Brenner, J Chataway, R. Hughes, K. Smith, D. Miller, and R Kapoor
Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis
Multiple Sclerosis,
September 1, 2008;
14(8):
1068 - 1075.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Minneboo, B Jasperse, F Barkhof, B M J Uitdehaag, D L Knol, V de Groot, C H Polman, and J A Castelijns
Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters
J. Neurol. Neurosurg. Psychiatry,
August 1, 2008;
79(8):
917 - 923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Miller, V. Spada, D. Beerkircher, and R. R. Kreitman
Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing--remitting multiple sclerosis
Multiple Sclerosis,
May 1, 2008;
14(4):
494 - 499.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D Horakova, J L Cox, E Havrdova, S Hussein, O Dolezal, D Cookfair, M G Dwyer, Z Seidl, N Bergsland, M Vaneckova, et al.
Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study
J. Neurol. Neurosurg. Psychiatry,
April 1, 2008;
79(4):
407 - 414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Duan, P.G. Hildenbrand, M.P. Sampat, D.F. Tate, I. Csapo, B. Moraal, R. Bakshi, F. Barkhof, D.S. Meier, and C.R.G. Guttmann
Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis
AJNR Am. J. Neuroradiol.,
February 1, 2008;
29(2):
340 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.A. Rocca, T. Mondria, P. Valsasina, M.P. Sormani, Z.H. Flach, P.A. Te Boekhorst, G. Comi, R.Q. Hintzen, and M. Filippi
A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis
AJNR Am. J. Neuroradiol.,
October 1, 2007;
28(9):
1659 - 1661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Roccatagliata, M. Rocca, P. Valsasina, L. Bonzano, M. Sormani, R. Saccardi, G. Mancardi, M. Filippi, and for the Italian GITMO-NEURO Intergroup on Autologo
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study
Multiple Sclerosis,
September 1, 2007;
13(8):
1068 - 1070.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Gauthier, M. Mandel, C.R.G. Guttmann, B. I. Glanz, S. J. Khoury, R. A. Betensky, and H. L. Weiner
Predicting short-term disability in multiple sclerosis
Neurology,
June 12, 2007;
68(24):
2059 - 2065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Khan
Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?
Neurology,
May 29, 2007;
68(22_suppl_3):
S64 - S71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, M. Ukmar, A. Bratina, C. Maggiore, A. Bosco, A. Grop, et al.
I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy
Multiple Sclerosis,
May 1, 2007;
13(4):
490 - 501.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Banwell, M. Shroff, J. M. Ness, D. Jeffery, S. Schwid, B. Weinstock-Guttman, and for the International Pediatric MS Study Group
MRI features of pediatric multiple sclerosis
Neurology,
April 17, 2007;
68(16_suppl_2):
S46 - S53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Juha, S. Leszek, F. Sten, H. Jan, B. Jakob, F. Olof, and K. W. Maria
Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development
J. Neurol. Neurosurg. Psychiatry,
April 1, 2007;
78(4):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jasperse, A. Minneboo, V. de Groot, N. F. Kalkers, P. E. van Helden, B. M. J. Uitdehaag, F. Barkhof, and C. H. Polman
Determinants of Cerebral Atrophy Rate at the Time of Diagnosis of Multiple Sclerosis
Arch Neurol,
February 1, 2007;
64(2):
190 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Audoin, D Ibarrola, I Malikova, E Soulier, S Confort-Gouny, M-V A. Duong, F Reuter, P Viout, A Ali-Cherif, P J Cozzone, et al.
Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI study of corpus callosum
Multiple Sclerosis,
January 1, 2007;
13(1):
41 - 51.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J H Simon
Brain atrophy in multiple sclerosis: what we know and would like to know
Multiple Sclerosis,
November 1, 2006;
12(6):
679 - 687.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Wegner, M. M. Esiri, S. A. Chance, J. Palace, and P. M. Matthews
Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.
Neurology,
September 26, 2006;
67(6):
960 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Leocani, M Rovaris, F M Boneschi, S Medaglini, P Rossi, V Martinelli, S Amadio, and G Comi
Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study
J. Neurol. Neurosurg. Psychiatry,
September 1, 2006;
77(9):
1030 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C C Ford, K P Johnson, R P Lisak, H S Panitch, G Shifroni, J S Wolinsky, and The Copaxone(R) Study Group
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
Multiple Sclerosis,
June 1, 2006;
12(3):
309 - 320.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al.
APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers
Neurology,
May 9, 2006;
66(9):
1373 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.H. Simon, D. Li, A. Traboulsee, P.K. Coyle, D.L. Arnold, F. Barkhof, J.A. Frank, R. Grossman, D.W. Paty, E.W. Radue, et al.
Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines.
AJNR Am. J. Neuroradiol.,
February 1, 2006;
27(2):
455 - 461.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R A Rudick, G R Cutter, M Baier, B Weinstock-Guttman, M K Mass, E Fisher, D M Miller, and A W Sandrock
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
Multiple Sclerosis,
December 1, 2005;
11(6):
626 - 634.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. M. Pomeroy, P. M. Matthews, J. A. Frank, E. K. Jordan, and M. M. Esiri
Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis
Brain,
November 1, 2005;
128(11):
2713 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Bermel, S. R. Puli, R. A. Rudick, B. Weinstock-Guttman, E. Fisher, F. E. Munschauer III, and R. Bakshi
Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity
Arch Neurol,
September 1, 2005;
62(9):
1371 - 1376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sastre-Garriga, G. T. Ingle, D. T. Chard, M. Cercignani, L. Ramio-Torrenta, D. H. Miller, and A. J. Thompson
Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study
Brain,
June 1, 2005;
128(6):
1454 - 1460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J Fox, E. Fisher, J. Tkach, J.-C. Lee, J. A Cohen, and R. A Rudick
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
Multiple Sclerosis,
April 1, 2005;
11(2):
140 - 145.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, et al.
Identifying and treating patients with suboptimal responses
Neurology,
December 28, 2004;
63(12_suppl_6):
S33 - S40.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue
The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis
Neurology,
December 14, 2004;
63(11_suppl_5):
S3 - S11.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. A. Cohen and J. P. Antel
Does interferon beta help in secondary progressive MS?
Neurology,
November 23, 2004;
63(10):
1768 - 1769.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Wei, C. R. Guttmann, S. K Warfield, M. Eliasziw, and J R. Mitchell
Has your patient's multiple sclerosis lesion burden or brain atrophy actually changed?
Multiple Sclerosis,
August 1, 2004;
10(4):
402 - 406.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Sharma, M. P. Sanfilipo, R. H. B. Benedict, B. Weinstock-Guttman, F. E. Munschauer III, and R. Bakshi
Whole-Brain Atrophy in Multiple Sclerosis Measured by Automated versus Semiautomated MR Imaging Segmentation
AJNR Am. J. Neuroradiol.,
June 1, 2004;
25(6):
985 - 996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Malmestrom, S. Haghighi, L. Rosengren, O. Andersen, and J. Lycke
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
Neurology,
December 23, 2003;
61(12):
1720 - 1725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rovaris, F. Agosta, M. P. Sormani, M. Inglese, V. Martinelli, G. Comi, and M. Filippi
Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study
Brain,
October 1, 2003;
126(10):
2323 - 2332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
